WallStreetZenWallStreetZen

NASDAQ: APVO
Aptevo Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Aptevo Therapeutics earnings were -$28.1M for the trailing 12 months ending Jun 30, 2026, with -99.8% growth year over year. The latest APVO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$6.4M, down 6.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, APVO reported annual earnings of -$27.5M, with 14.1% growth. The next APVO earnings date is Nov 5, 2026.

APVO past earnings growth

How has APVO's earnings growth performed historically?

Company
-99.75%
Industry
18.1%
Market
92.82%
APVO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
APVO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

APVO earnings history

Current Revenue
$0.0
Current Earnings
-$28.1M
Current Profit Margin
0%

APVO Return on Equity

Current Company
-214.2%
Current Industry
-13.6%
Current Market
30.9%
APVO's Return on Equity (-214.2%)... subscribe to Premium to read more.
High Return on Equity Performance

APVO Return on Assets

Current Company
-126.7%
Current Industry
-10.2%
APVO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when APVO announces earnings.

APVO Return on Capital Employed

Current Company
-283.01%
Current Industry
-6.7%
APVO's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

APVO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
APVO-$24.58M-$28.08M-90.37%$66.91
XRTX-$2.62M-$2.70MN/A-$1.86
CLDI-$15.59M-$23.46MN/A-$38.24
ADXN-$8.58M-$8.60MN/A-$0.06
GOVX-$20.37M-$20.43MN/A-$9.59
View Top Biotech Stocks

APVO earnings dates

Next earnings date
Nov 5, 2026

Aptevo Therapeutics Earnings Reports & History FAQ

What were Aptevo Therapeutics's earnings last quarter?

On APVO's earnings call on Aug 17, 2026, Aptevo Therapeutics (NASDAQ: APVO) reported Q2 2026 earnings per share (EPS) of -$5.31, up 96.49% year over year. Total APVO earnings for the quarter were -$6.36 million. In the same quarter last year, Aptevo Therapeutics's earnings per share (EPS) was -$151.29.

If you're new to stock investing, here's how to buy Aptevo Therapeutics stock.

When does Aptevo Therapeutics report earnings?

The next APVO earnings date is Nov 5, 2026. Add APVO to your watchlist to be reminded of Aptevo Therapeutics's next earnings date.

Is Aptevo Therapeutics profitable or losing money?

As of the last Aptevo Therapeutics earnings report, Aptevo Therapeutics is currently losing money. Aptevo Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$26.41 million, a 9.92% increase year over year.

What was APVO's earnings growth in the past year?

As of Aptevo Therapeutics's earnings date in Aug 17, 2026, Aptevo Therapeutics's earnings has grown -99.75% year over year. This is 117.85 percentage points lower than the US Biotechnology industry earnings growth rate of 18.1%. APVO earnings in the past year totalled -$28.08 million.

What are Aptevo Therapeutics's earnings expectations?

The current EPS estimate for Aptevo Therapeutics's earnings report in Nov 5, 2026 is -$4.46.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.